The following is a summary of “Evaluating sensitization-associated, neuropathic-like symptoms and psychological factors in ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...

The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...

Patients with vs without keloids had a higher prevalence of interstitial lung disease after controlling for patient specific factors.

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...

A panel of experts, including Dr Rohit Aggarwal, Principal Investigator of the decentralized Myositis Interstitial Lung ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...